Independent directory Public ClinicalTrials.gov records United States
Clinical Trials Finder
Objective public record navigation
Search Results

Search by objective public record fields.

Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results are retrieved from ClinicalTrials.gov and synchronized into the directory. Search pages remain noindex by default.

Clear filters
ClinicalTrials.gov public records Last synced Sep 23, 2026, 12:40 PM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 1–24 of 41 matching trials from the live ClinicalTrials.gov search.
Local D1 index available.
Filters: Condition: Chronic Allograft Nephropathy Clear all
Completed Phase 4 Interventional

The Comparison of Tacrolimus and Sirolimus Immunosuppression Based Drug Regimens in Kidney Transplant Recipients

NCT00275535
View directory record Official record
Conditions
Kidney Diseases
Interventions
Anti-thymocyte globulin, Mycophenolate mofetil, Prednisone, Tacrolimus, Sirolimus
Drug
Lead sponsor
Mayo Clinic
Other
Eligibility
18 Years to 75 Years
Enrollment
165 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2001 – 2008
U.S. locations
1
States / cities
Rochester, Minnesota
Source: ClinicalTrials.gov public record
Updated Dec 7, 2011 · Synced Sep 23, 2026, 12:40 PM EDT
Withdrawn Phase 2 Interventional

Study of STX-100 in Renal Transplant Patients With Interstitial Fibrosis and Tubular Atrophy (IF/TA)

NCT00878761
View directory record Official record
Conditions
Chronic Allograft Dysfunction
Interventions
STX-100
Biological
Lead sponsor
Stromedix, Inc.
Industry
Eligibility
18 Years to 65 Years
Enrollment
48 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2010 – 2011
U.S. locations
1
States / cities
Cambridge, Massachusetts
Source: ClinicalTrials.gov public record
Updated May 22, 2011 · Synced Sep 23, 2026, 12:40 PM EDT
Completed Phase 1Phase 2 Interventional Results available

Renal Allograft Tolerance Through Mixed Chimerism

NCT01780454
View directory record Official record
Conditions
End Stage Renal Disease
Interventions
MEDI-507, Rituximab, Total Body Irradiation, Thymic Irradiation
Drug · Radiation
Lead sponsor
Massachusetts General Hospital
Other
Eligibility
18 Years to 65 Years
Enrollment
2 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2013 – 2020
U.S. locations
1
States / cities
Boston, Massachusetts
Source: ClinicalTrials.gov public record
Updated Apr 18, 2021 · Synced Sep 23, 2026, 12:40 PM EDT
Recruiting No phase listed Observational

Decellularized Femoral Artery Allograft (Nexeon AVX) Prospective Registry

NCT05880537
View directory record Official record
Conditions
End-Stage Renal Disease
Interventions
Nexeon Arterial Venous Allograft
Other
Lead sponsor
LifeNet Health
Industry
Eligibility
18 Years and older
Enrollment
100 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2023 – 2028
U.S. locations
4
States / cities
Mobile, Alabama • Sylmar, California • Torrance, California + 1 more
Source: ClinicalTrials.gov public record
Updated Sep 14, 2026 · Synced Sep 23, 2026, 12:40 PM EDT
Completed No phase listed Observational

Angiotensin-Converting Enzyme Gene Polymorphism and the Risk of Chronic Allograft Nephropathy

NCT00006328
View directory record Official record
Conditions
Kidney Disease
Interventions
Not listed
Lead sponsor
National Center for Research Resources (NCRR)
NIH
Eligibility
18 Years and older
Healthy volunteers
Healthy volunteers not accepted
U.S. locations
1
States / cities
Ann Arbor, Michigan
Source: ClinicalTrials.gov public record
Updated Jun 23, 2005 · Synced Sep 23, 2026, 12:40 PM EDT
Completed Phase 1 Interventional Results available

Renal Allograft Tolerance Through Mixed Chimerism (Belatacept)

NCT02314403
View directory record Official record
Conditions
Kidney Failure, Chronic, Renal Insufficiency
Interventions
Belatacept, ATG, Rituximab, Total Body Irradiation, Thymic Irradiation, Combined Bone Marrow/Kidney Transplantation
Drug · Radiation · Procedure
Lead sponsor
Massachusetts General Hospital
Other
Eligibility
18 Years to 60 Years
Enrollment
2 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2015 – 2021
U.S. locations
1
States / cities
Boston, Massachusetts
Source: ClinicalTrials.gov public record
Updated Oct 24, 2021 · Synced Sep 23, 2026, 12:40 PM EDT
Recruiting No phase listed Observational

Proteogenomic Monitoring and Assessment of Kidney Transplant Recipients

NCT01531257
View directory record Official record
Conditions
Acute Rejection (AR) of Transplanted Kidney, Chronic Allograft Nephropathy (CAN), Interstitial Fibrosis (IF), Tubular Atrophy (TA)
Interventions
Not listed
Lead sponsor
Northwestern University
Other
Eligibility
18 Years and older
Enrollment
1,000 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2010 – 2027
U.S. locations
1
States / cities
Chicago, Illinois
Source: ClinicalTrials.gov public record
Updated May 4, 2026 · Synced Sep 23, 2026, 12:40 PM EDT
Not yet recruiting No phase listed Observational

Microvasculature Ultrasound Super-resolution in Transplant Delayed Graft Function

NCT07645599
View directory record Official record
Conditions
End Stage Chronic Renal Failure, Renal Transplant, Microvascular Changes, Microvascular Circulation
Interventions
Ultrasound contrast agent (Contrast-enhanced ultrasound), Optison (Perflutren Protein-Type A Microspheres Injectable Suspension), Lumason® contrast agent, DEFINITY®
Diagnostic Test · Drug
Lead sponsor
Roderick Tan
Other
Eligibility
18 Years and older
Enrollment
40 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2026 – 2028
U.S. locations
1
States / cities
Pittsburgh, Pennsylvania
Source: ClinicalTrials.gov public record
Updated Jun 11, 2026 · Synced Sep 23, 2026, 12:40 PM EDT
Completed Phase 1Phase 2 Interventional Results available

C1INH Inhibitor Preoperative and Post Kidney Transplant to Prevent DGF & IRI

NCT02134314
View directory record Official record
Conditions
End Stage Renal Disease, Kidney Failure, Delayed Graft Function, Ischemic Reperfusion Injury
Interventions
C1 Esterase Inhibitor, Placebo
Drug
Lead sponsor
Cedars-Sinai Medical Center
Other
Eligibility
18 Years to 70 Years
Enrollment
70 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2014 – 2017
U.S. locations
1
States / cities
Los Angeles, California
Source: ClinicalTrials.gov public record
Updated Jun 24, 2018 · Synced Sep 23, 2026, 12:40 PM EDT
Enrolling by invitation Phase 2 Interventional

Long-Term Safety and Efficacy of Tegoprubart in Kidney Transplant Recipients

NCT06126380
View directory record Official record
Conditions
Kidney Transplant Rejection
Interventions
AT-1501, Tacrolimus
Drug
Lead sponsor
Eledon Pharmaceuticals
Industry
Eligibility
18 Years to 100 Years
Enrollment
132 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2023 – 2029
U.S. locations
26
States / cities
Los Angeles, California • Orange, California • Sacramento, California + 22 more
Source: ClinicalTrials.gov public record
Updated Dec 9, 2025 · Synced Sep 23, 2026, 12:40 PM EDT
Completed Phase 1Phase 2 Interventional Results available

Berinert (C1INH) vs Placebo for DGF/IRI

NCT04696146
View directory record Official record
Conditions
End Stage Renal Disease, Chronic Kidney Diseases
Interventions
Berinert, Placebo
Drug
Lead sponsor
Cedars-Sinai Medical Center
Other
Eligibility
18 Years to 70 Years
Enrollment
45 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2021 – 2024
U.S. locations
1
States / cities
Los Angeles, California
Source: ClinicalTrials.gov public record
Updated Dec 3, 2024 · Synced Sep 23, 2026, 12:40 PM EDT
Terminated Phase 2 Interventional

Improving Transplant Options of Highly Sensitized Recipients Using IGIV-C, 10%

NCT00090194
View directory record Official record
Conditions
Kidney Failure, Chronic
Interventions
Immune Globulin Intravenous (Human), 10%
Biological
Lead sponsor
National Institute of Allergy and Infectious Diseases (NIAID)
NIH
Eligibility
1 Year to 70 Years
Enrollment
56 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2003 – 2004
U.S. locations
16
States / cities
Birmingham, Alabama • Phoenix, Arizona • Los Angeles, California + 12 more
Source: ClinicalTrials.gov public record
Updated Jan 10, 2017 · Synced Sep 23, 2026, 12:40 PM EDT
Completed Phase 3 Interventional

Prevention of Kidney Transplant Rejection

NCT00005010
View directory record Official record
Conditions
End-Stage Renal Disease, Chronic Allograft Nephropathy
Interventions
Irbesartan, Pravastatin
Drug
Lead sponsor
National Institute of Allergy and Infectious Diseases (NIAID)
NIH
Eligibility
18 Years and older
Healthy volunteers
Healthy volunteers not accepted
Timeline
Ends 2004
U.S. locations
1
States / cities
Rockville, Maryland
Source: ClinicalTrials.gov public record
Updated Jan 24, 2013 · Synced Sep 23, 2026, 12:40 PM EDT
Recruiting Phase 1Phase 2 Interventional

Safety, Pharmacokinetics, and Efficacy of AT 1501 in Patients Undergoing Kidney Transplant

NCT05027906
View directory record Official record
Conditions
Prevention of Rejection in Kidney Transplant
Interventions
AT-1501
Drug
Lead sponsor
Eledon Pharmaceuticals
Industry
Eligibility
18 Years to 100 Years
Enrollment
48 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2022 – 2027
U.S. locations
1
States / cities
Cincinnati, Ohio
Source: ClinicalTrials.gov public record
Updated Jun 28, 2025 · Synced Sep 23, 2026, 12:40 PM EDT
Terminated Phase 3 Interventional Results available

The Everolimus-Transplant Exit Strategy Trial (E-TEST)

NCT01636466
View directory record Official record
Conditions
Kidney Failure, Chronic
Interventions
Everolimus
Drug
Lead sponsor
Ashtar Chami
Other
Eligibility
18 Years to 75 Years
Enrollment
1 participant
Healthy volunteers
Healthy volunteers not accepted
Timeline
2013 – 2014
U.S. locations
1
States / cities
Atlanta, Georgia
Source: ClinicalTrials.gov public record
Updated Feb 4, 2018 · Synced Sep 23, 2026, 12:40 PM EDT
Completed Not applicable Interventional

Nonmyeloablative Allogeneic Transplant

NCT01272817
View directory record Official record
Conditions
Aplastic Anemia, Paroxysmal Nocturnal Hemoglobinuria, Acute Myelogenous Leukemia, Acute Lymphocytic Leukemia, Myelodysplastic Syndrome, Chronic Myelogenous Leukemia, Chronic Lymphocytic Leukemia, Hodgkin's Lymphoma, Non-Hodgkin's Lymphoma, Mantle Cell Lymphoma, Multiple Myeloma, Waldenstrom Macroglobulinemia, Breast Cancer, Renal Cell Carcinoma, Melanoma, Sarcoma, Ovarian Cancer, Thymoma
Interventions
Nonmyeloablative Allogeneic Transplant
Procedure
Lead sponsor
Scripps Health
Other
Eligibility
18 Years to 72 Years
Enrollment
36 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2001 – 2015
U.S. locations
1
States / cities
La Jolla, California
Source: ClinicalTrials.gov public record
Updated Nov 22, 2022 · Synced Sep 23, 2026, 12:40 PM EDT
Terminated Phase 3 Interventional

A Study to Compare Treatment With Sirolimus Versus Standard Treatment in Patients Who Have Received a Kidney Transplant

NCT00005113
View directory record Official record
Conditions
End-Stage Renal Disease, Kidney Transplantation
Interventions
Cyclosporine, Sirolimus, Tacrolimus
Drug
Lead sponsor
Boston Children's Hospital
Other
Eligibility
Up to 20 Years
Enrollment
102 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
1999 – 2006
U.S. locations
1
States / cities
Boston, Massachusetts
Source: ClinicalTrials.gov public record
Updated Mar 12, 2012 · Synced Sep 23, 2026, 12:40 PM EDT
Completed No phase listed Observational

VIRTUUS Children's Study

NCT03719339
View directory record Official record
Conditions
Renal Transplant Rejection, Pediatric Kidney Disease, End Stage Renal Disease, Nephropathy, BK Virus (Nephropathy), Antibody-mediated Rejection, Acute Cellular Graft Rejection
Interventions
Not listed
Lead sponsor
Children's Hospital of Philadelphia
Other
Eligibility
2 Years to 18 Years
Enrollment
445 participants
Timeline
2017 – 2026
U.S. locations
12
States / cities
La Jolla, California • Los Angeles, California • Palo Alto, California + 7 more
Source: ClinicalTrials.gov public record
Updated Jul 5, 2026 · Synced Sep 23, 2026, 12:40 PM EDT
Completed Phase 2 Interventional Results available

Combined Kidney and Bone Marrow Transplantation to Prevent Kidney Transplant Rejection

NCT00801632
View directory record Official record
Conditions
Kidney Transplantation, Kidney Failure, Chronic
Interventions
Kidney Transplantation, Bone marrow transplantation, MEDI-507, cyclophosphamide, rituximab, Tacrolimus, corticosteroids, thymic irradiation
Procedure · Biological · Drug + 1 more
Lead sponsor
National Institute of Allergy and Infectious Diseases (NIAID)
NIH
Eligibility
18 Years to 60 Years
Enrollment
5 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2008 – 2014
U.S. locations
1
States / cities
Boston, Massachusetts
Source: ClinicalTrials.gov public record
Updated Nov 9, 2015 · Synced Sep 23, 2026, 12:40 PM EDT
Completed Phase 2 Interventional

Safety and Efficacy of Tegoprubart in Patients Undergoing Kidney Transplantation

NCT05983770
View directory record Official record
Conditions
Kidney Transplant Rejection
Interventions
AT-1501, Tacrolimus
Drug
Lead sponsor
Eledon Pharmaceuticals
Industry
Eligibility
18 Years to 100 Years
Enrollment
127 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2023 – 2025
U.S. locations
27
States / cities
Los Angeles, California • Orange, California • Sacramento, California + 23 more
Source: ClinicalTrials.gov public record
Updated Jul 21, 2026 · Synced Sep 23, 2026, 12:40 PM EDT
Not listed No phase listed Observational

Study of Subclinical Viral Infection

NCT01615341
View directory record Official record
Conditions
Kidney Transplantation, Kidney Failure, Chronic
Interventions
Not listed
Lead sponsor
Seattle Children's Hospital
Other
Eligibility
1 Year to 25 Years
Enrollment
100 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2011 – 2016
U.S. locations
1
States / cities
Seattle, Washington
Source: ClinicalTrials.gov public record
Updated Jun 7, 2012 · Synced Sep 23, 2026, 12:40 PM EDT
Completed Not applicable Interventional

Antibody and Delayed Cyclosporine Versus Initial Cyclosporine Alone in Patients Receiving Kidney Transplants

NCT00007787
View directory record Official record
Conditions
Kidney Transplantation, Chronic Allograft Nephropathy
Interventions
Cyclosporine, Anti-human thymocyte globulin (rabbit), Tacrolimus
Biological · Drug
Lead sponsor
National Institute of Allergy and Infectious Diseases (NIAID)
NIH
Eligibility
21 Years and older
Enrollment
350 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2000 – 2004
U.S. locations
1
States / cities
Rockville, Maryland
Source: ClinicalTrials.gov public record
Updated Jan 22, 2013 · Synced Sep 23, 2026, 12:40 PM EDT
Completed Phase 4 Interventional Results available

Angiotensin II Blockade for Chronic Allograft Nephropathy

NCT00067990
View directory record Official record
Conditions
Kidney Disease, Proteinuria
Interventions
Losartan 100mg, Placebo
Drug
Lead sponsor
University of Minnesota
Other
Eligibility
18 Years and older
Enrollment
153 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2002 – 2011
U.S. locations
2
States / cities
Minneapolis, Minnesota
Source: ClinicalTrials.gov public record
Updated Sep 17, 2017 · Synced Sep 23, 2026, 12:40 PM EDT
Completed No phase listed Observational

New Strategies for Non-invasive Detection of Chronic Allograft Nephropathy

NCT00283348
View directory record Official record
Conditions
Chronic Rejection
Interventions
Not listed
Lead sponsor
Virginia Commonwealth University
Other
Eligibility
18 Years to 70 Years
Enrollment
121 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2006 – 2008
U.S. locations
1
States / cities
Richmond, Virginia
Source: ClinicalTrials.gov public record
Updated Mar 19, 2017 · Synced Sep 23, 2026, 12:40 PM EDT